Bupropion hydrochloride
You should keep this leaflet, so that you can read it again if you need to.
In case of any further doubts, you should consult a doctor or pharmacist.
This medicine has been prescribed specifically for you. Do not pass it on to others.
The medicine may harm another person, even if their symptoms are the same.
If the patient experiences any side effects, including any side effects not listed in this leaflet, they should tell their doctor or pharmacist. See section 4.
Wellbutrin XR is a prescription-only medicine used to treat depression. It acts on the chemicals in the brain called norepinephrineand dopamine.
If any of the above situations apply to the patient, they should contact their doctor immediately without taking Wellbutrin XR.
Before starting to take Wellbutrin XR, the patient should discuss it with their doctor or pharmacist.
Wellbutrin XR is not recommended for the treatment of children under 18 years of age.
In children under 18 years of age treated with antidepressants, there is an increased risk of
suicidal thoughts and behaviors.
Wellbutrin XR may cause seizures in about 1 in 1000 patients. The occurrence of this side effect is more likely in patients with the above-mentioned conditions.
If seizures occur during treatment, the patient should stop taking Wellbutrin XR.
The patient should not take any more of this medicine and should contact their doctorimmediately.
If any of the above situations apply to the patient, they should contact their doctor before starting to take Wellbutrin XR. The doctor may decide to monitor the patient closely or recommend alternative treatment.
In patients with depression, suicidal thoughts or behaviors may sometimes occur. Such behaviors may worsen when the patient first starts taking antidepressants, as it takes some time, usually about two weeks, but sometimes longer, for these medicines to start working.
Such thoughts may occur more frequently:
If the patient has had suicidal thoughts or self-harm thoughts before.
If the patient is a young adult. Clinical studies have shown an increased risk of suicidal behavior in adults (under 25 years of age) with mental disorders who were treated with antidepressants.
In case of suicidal thoughts or self-harm thoughts, the patient should immediately contact their doctor or go to the hospital.
It may be helpful to inform a relative or friendthat the patient has depression, and ask them to read this leaflet. The patient may ask them to tell them if they notice that their depression is getting worse or if changes in their behavior become worrying.
If the patient is currently taking or has taken within the last 14 days other antidepressant medicines calledmonoamine oxidase inhibitors (MAOIs), they should contact their doctor without taking Wellbutrin XR(see also: "When not to take Wellbutrin XR", in section 2).
have recently taken, as well as those they plan to take, including herbal medicines or vitamins, including those available without a prescription. The doctor may change the dose of Wellbutrin XR, recommend a change in dosing, or discontinue other medicines being taken.
Some medicines should not be taken at the same time as Wellbutrin XR. Some of them may increase the risk of seizures or convulsions. Other medicines may increase the risk of other side effects. Examples of such medicines are listed below, but this is not an exhaustive list.
If any of the above situations apply to the patient, they should contact their doctor immediately before starting to take Wellbutrin XR. The doctor will assess the risk and benefits of using Wellbutrin XR.
exacerbation of reflexes, muscle stiffness, lack of coordination, and (or) gastrointestinal disorders (e.g., nausea, vomiting, diarrhea).
If any of the above situations apply to the patient, they should contact their doctor immediately before starting to take Wellbutrin XR.
Alcohol may affect the action of Wellbutrin XR, and their concurrent use may, although rarely, cause nervousness or changes in mental state. Some patients become more sensitive to alcohol while taking Wellbutrin XR. The doctor may recommend abstaining from alcohol (beer, wine, spirits) or significantly reducing its consumption while taking Wellbutrin XR. If the patient is currently drinking large amounts of alcohol, they should not stop drinking suddenly, as this may cause a seizure.
The patient should discuss drinking alcohol with their doctorbefore starting to take Wellbutrin XR.
Wellbutrin XR may affect the results of laboratory tests for the presence of other medicines. If the patient is undergoing such a test, they should inform their doctor or nurse that they are taking Wellbutrin XR.
If the patient is pregnant, thinks they may be pregnant, or plans to have a baby, they should not take Wellbutrin XR unless their doctor recommends it. Before using this medicine during pregnancy, the patient should consult their doctor or pharmacist. Some, but not all, studies suggest an increased risk of congenital defects, particularly heart defects, in children whose mothers used Wellbutrin XR. It is not known whether this was caused by the use of this medicine.
The ingredients of Wellbutrin XR may pass into breast milk. Before using Wellbutrin XR, the patient should consult their doctor or pharmacist.
If Wellbutrin XR causes dizziness or a feeling of emptiness in the head, the patient should not drive vehicles or operate machines.
This medicine should always be taken as directed by the doctor or pharmacist. The doctor will recommend a dose individually for the patient. In case of doubts, the patient should consult their doctor or pharmacist.
Improvement in the patient's condition may occur only after some time. The full effect of the medicine may only become apparent after several weeks or months. Even if the patient starts to feel better, the doctor may recommend continuing to take Wellbutrin XR to prevent a relapse of depression.
Wellbutrin XR is available in a dose of 150 mg and 300 mg.
What dose to take
Usually, the recommended dose for adults is one150 mg tablet once a day.
The doctor may recommend increasing the dose to 300 mg once a day, if after several weeks of treatment, the patient does not show improvement.
The tablet is coated with a shell that slowly releases the medicine into the digestive tract. The patient may notice something in their stool that looks like a tablet. This is the empty shell that has been eliminated from the body.
The patient should not chew, crush, or divide them – if this happens, there is a risk of overdose due to the rapid release of the medicine into the body. This may increase the risk of side effects, including seizures.
For some patients, a dose of 150 mg once a day is sufficientthroughout the treatment period. The doctor may recommend this dosing if the patient has liver or kidney disease.
How long to take the treatment
It may take weeks or monthsbefore any improvement is observed. The patient should regularly consult their doctor to assess their depressive symptoms, so that it can be decided how long they should be treated. If the patient feels better, the doctor may recommend continuing to take Wellbutrin XR to prevent a relapse of depression.
Taking too many tablets may cause seizures or convulsions. Do not delay. The patient should contact their doctor or the nearest hospital emergency department immediately.
In case of a missed dose, the patient should wait and take the next dose at the usual time. The patient should not take a double doseto make up for the missed dose.
The patient should not stoptaking Wellbutrin XR or reduce the dose without first discussing it with their doctor.
In case of any further doubts about the use of this medicine, the patient should consult their doctor or pharmacist.
Like all medicines, Wellbutrin XR can cause side effects, although not everybody gets them.
About 1 in 1000 patients taking Wellbutrin XR may experience seizures (convulsions). The likelihood of this happening is higher if the patient takes higher doses than recommended, takes certain medicines, or is at increased risk of seizures.
In case of doubts, the patient should consult their doctor.
If the patient experiences a seizure, they should contact their doctor.
The patient should not take any more of this medicine.
Allergic reactions
Some patients may experience allergic reactions to Wellbutrin XR. These include:
If the patient experiences any symptoms of an allergic reaction, they should contact their doctor immediately.
The patient should not take any more of this medicine.
If the doctor has prescribed medicines to relieve allergic symptoms, the patient should take the entire course.
Systemic lupus erythematosus or worsening of lupus symptoms
Frequency not known - frequency cannot be estimated from the available data from patients taking Wellbutrin XR. Lupus is an immune system disorder that affects the skin and other organs.
as it may be necessary to stop the treatment.
Acute generalized exanthematous pustulosis
Frequency not known - frequency cannot be estimated from the available data from patients taking Wellbutrin XR. Symptoms of acute generalized exanthematous pustulosis include a skin rash with pustules/blisters filled with pus.
as it may be necessary to stop the treatment.
May affect more than 1 in 10patients:
May affect up to 1 in 10patients:
May affect up to 1 in 100patients:
May affect up to 1 in 1,000patients:
May affect up to 1 in 10,000patients:
Other side effects have occurred in a small number of patients, but their exact frequency is unknown:
exacerbation of reflexes, muscle stiffness, lack of coordination, and (or) gastrointestinal disorders (e.g., nausea, vomiting, diarrhea) when taking Wellbutrin XR with medicines used to treat depression (such as paroxetine, citalopram, escitalopram, fluoxetine, and venlafaxine).
If the patient experiences any side effects, including any side effects not listed in this leaflet, they should tell their doctor or pharmacist. Side effects can be reported directly to the Department of Drug Safety, Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products, Al. Jerozolimskie 181C, 02-222 Warsaw, Tel.: +48 22 49 21 301, Fax: +48 22 49 21 309, website: https://smz.ezdrowie.gov.pl. By reporting side effects, more information can be collected on the safety of this medicine.
The medicine should be stored out of sight and reach of children.
The patient should not use this medicine after the expiry date stated on the packaging. The expiry date refers to the last day of the month.
The medicine should be stored in its original packaging to protect it from light and moisture.
The bottle contains a small, tightly closed desiccant with activated carbon and silica gel, which helps keep the tablets dry. The desiccant should be left in the bottle.
The patient should not swallow it.
Medicines should not be disposed of via wastewater or household waste. The patient should ask their pharmacist how to dispose of medicines that are no longer needed. This will help protect the environment.
The active substance of Wellbutrin XR is bupropion hydrochloride. Each tablet contains 150 mg of bupropion hydrochloride.
The other ingredients are:
Core:
Polyvinyl alcohol
Glycerol dibehenate
Coating:
Ink:
Opacode S-1-17823
Lacquer (20% esterified), iron oxide black (E 172), and concentrated ammonium hydroxide.
Wellbutrin XR 150 mg tabletsare cream-white to light yellow, round, with the inscription "GS 5FV 150" in black on one side of the tablet, and the other side is smooth. The tablets are available in white polyethylene bottles of 30 tablets.
For more detailed information, the patient should contact the marketing authorization holder or the parallel importer.
GlaxoSmithKline – Produtos Farmacêuticos, Lda.
Rua Dr. António Loureiro Borges, 3
Arquiparque – Miraflores
1495-131 Algés
Portugal
Aspen Bad Oldesloe GmbH, Industriestrasse 32-36,
23843 Bad Oldesloe, Germany
Glaxo Wellcome S.A., Avenida de Extremadura 3,
09400 Aranda de Duero, Burgos, Spain
ProCarePlus Pharma S.A.
ul. Bobrzyńskiego 14
30-348 Kraków
CANPOLAND SPÓŁKA AKCYJNA
ul. Beskidzka 190
91-610 Łódź
Chemiczno-Farmaceutyczna Spółdzielnia Pracy "ESPEFA"
ul. Juliusza Lea 208
30-133 Kraków
MEDICOFARMA S.A.
Inner coating: | Outer coating: |
Ethylcellulose | Polyethylene glycol 1450 |
Povidone K-90 | Methacrylic acid and ethyl acrylate copolymer (1:1) dispersion (Eudragit L30 D-55) |
Polyethylene glycol 1450 | Silica colloidal |
Triethyl citrate |
ul. Sokołowska 9 lok. U19
01-142 Warszawa
Marketing authorization number in Portugal, the country of export: 5015565
Wellbutrin XR:
Austria, Belgium, Cyprus, Greece, Luxembourg, Malta, Poland, Portugal,
Slovenia, Netherlands.
Wellbutrin:
Italy.
Elontril:
Czech Republic, Estonia, Germany, Hungary, Italy, Lithuania, Portugal, Romania,
Slovakia, Spain, Netherlands.
Wellbutrin Retard: Iceland, Norway.
Voxra:
Finland, Sweden.
Date of leaflet approval: 07.06.2022
[Information about the trademark]
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.